STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3451 by analyst upside · 2026-08-12
LLY
Eli Lilly and Company
Healthcare · Market Cap $1.08T · P/E 40.8x
ANALYST PRICE TARGET
+6.9%
implied upside to consensus target
Current Price $1215.02
Consensus Target $1299.01
Bull Target $1600.0
Bear Target $850.0
Analysts Covering 27
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
16
Hold
4
Sell
2
52-Week Low $644.5
52-Week High $1249.45
YTD Return +12.8%
FUNDAMENTALS
Market Cap $1.08T
P/E Ratio (TTM) 40.8x
Forward P/E 26.1x
EPS (TTM) $29.81
PEG Ratio 1.49
Dividend Yield 0.56%
Revenue (TTM) $79.7B
Profit Margin 33.5%
52-WEEK RANGE
52-Week Low $644.5
52-Week High $1249.45
Current Price $1215.02
Bear Target $850.0
Bull Target $1600.0
● Now $1215.02 ● Target $1299.01
TRADING DATA
Avg Volume 3.0M
YTD Return +12.8%
Analyst Count 27
Consensus Buy
Upside to Target +6.9%
Last Updated 2026-08-12

ANALYST SUMMARY

Eli Lilly and Company (LLY) is currently trading at $1215.02 with a Wall Street consensus price target of $1299.01, implying potential upside of 6.9% over the next 12 months. 27 analysts currently cover LLY, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1600.0, while the most cautious has a target of $850.0.

LLY operates in the Healthcare sector with a market capitalisation of $1.08T. The stock is up 12.8% year-to-date and is currently trading near the upper end of its 52-week range of $644.5 – $1249.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LLY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jefferies - Reiterated
Buy → Buy 2026-06-09 50% win rate (6 calls)
B of A Securities - Reiterated
Buy → Buy 2026-05-26 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-05 Building track record
Guggenheim reit
Buy → Buy 2026-05-05 62% win rate (8 calls)
Wolfe Research reit
Outperform → Outperform 2026-05-04 Building track record
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-05-01 40% win rate (10 calls)
Guggenheim - Reiterated
Buy → Buy 2026-04-22 62% win rate (8 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-04-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
57
out of 100
Coverage depth
25/30
Consensus clarity
18/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →